Immatics stock holds at USD 8.77 as analysts see upside

Immatics N.V. stock (NL0015255052) traded at USD 8.77 on Nasdaq on September 22, 2026, up USD 0.05 or 0.57 percent from the prior close of USD 8.72. The quoted level gives the market a clear reference point as analysts continue to see substantial valuation upside.

Analysts see a wide range

According to Zacks on September 22, 2026, eight analysts assigned Immatics an average price target of USD 17.60. Their target range extended from USD 11.80 to USD 25.00, putting the average target USD 8.88 above the latest closing price of USD 8.72.

The comparison is material: the average target represented 101.83 percent upside to the prior close, while even the lowest published target stood USD 3.08 above that reference price. The spread between the lowest and highest targets was USD 13.20, showing that expectations remain widely dispersed.

Valuation depends on clinical progress

Immatics develops T cell receptor based therapies for cancer, so the investment case depends heavily on clinical data, regulatory milestones and financing requirements rather than on a conventional earnings multiple. The current analyst range therefore describes a risk and reward profile with a large gap between the market quote and target assumptions.

For investors, the key distinction is between the quoted price and the evidence behind future pipeline value. The September 22, 2026 market snapshot showed a price of USD 8.77 and a daily gain of 0.57 percent, whereas the analyst average of USD 17.60 was based on forward expectations rather than the latest trading session.

IMTX remains below analyst average

Immatics stock closed at USD 8.77 on Nasdaq on September 22, 2026, compared with USD 8.72 at the previous close. The analyst average target of USD 17.60 was USD 8.83 above the September 22 quote, but the forecast range from USD 11.80 to USD 25.00 underlines the uncertainty around the path from current valuation to projected value.

More news and analyses on Immatics stock